Nektar Therapeutics

NKTR
Delayed Nasdaq - 09/20 10:00:00 pm
20.15USD
-0.35%
Prev.20.2200
Open20.2500
High20.7600
Low20.0200
Volume4 841 687
Financials
Sales 2019 106 M
EBIT 2019 -505 M
Net income 2019 -504 M
Debt 2019 129 M
Yield 2019 -
P/E ratio 2019 -6,99x
P/E ratio 2020 -7,06x
EV / Sales2019 34,5x
EV / Sales2020 16,6x
Capitalization 3 532 M
Company
Nektar Therapeutics specializes in the research and development of drugs for the treatment of cancer, autoimmune diseases and chronic pain. Net sales break down by source of income as follows:
- revenues from licensing and collaboration agreements (91.9%);
- product sales (4.6%);
- royalties...
Sector :
Biotechnology & Medical Research - NEC
Calendar :
2019-10-09 Presentation
Trading Rating :
Investor Rating :
Latest news
09/12NKTR CLASS ACTION ALERT : Bernstein Liebhard LLP Announces the Filing of a Securities Class Action Lawsuit Against Nektar Therapeutics
PR
09/04KESSLER TOPAZ MELTZER & CHECK, LLP : Announces Investor Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics
BU
09/03KESSLER TOPAZ MELTZER & CHECK, LLP : Securities Fraud Class Action Filed Against Nektar Therapeutics - NKTR
PR
08/30NEKTAR THERAPEUTICS : Other Events (form 8-K/A)
AQ
08/29NEKTAR THERAPEUTICS : ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR
PR
08/26NEKTAR THERAPEUTICS : Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nektar Therapeutics
BU
08/26DEADLINE REMINDER : The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nektar Therapeutics
BU
08/22INVESTOR ALERT - NEKTAR THERAPEUTICS (NKTR) - BRONSTEIN, GEWIRTZ & GROSSMAN, LLC NOTIFIES SHAREHOLDERS OF CLASS ACTION AND LEAD PLAINTIFF DEADLINE : October 18, 2019
PR
Technical analysis trends
Short TermMid-TermLong Term
TrendBullishBearishBearish
Resistance21,224,628,0
Spread/Res.-5,0%-18%-28%
Spread/Supp.8,4%19%19%
Support18,616,917,0